Ensuring data security in biotechnology: strategies and challenges

The rapid adoption of AI and big data technologies in the biotechnology sector presents unique data privacy and security challenges. To meet these challenges, BGI Genomics actively maintains certifications like ISO/IEC 27001 and BS 10012 while complying with rigorous regulatory standards, including GDPR.

ISO/IEC 27001 is a comprehensive framework that dictates the requirements for an information security management system (ISMS), essential for protecting a company’s financial data, intellectual property, and personal details entrusted by third parties. Meanwhile, BS 10012 specifically addresses the management of personal data, aligning with the stringent requirements of data protection regulations such as the GDPR.

In an insightful interview with AZoMedical, Dr. Fu Wei, Director of Quality Management at BGI Genomics, details the systematic and exhaustive process behind these certifications. This includes comprehensive audits involving document reviews, site visits, and management interviews, emphasizing the company’s ongoing commitment to excellence and security.

BGI Genomics integrates quality management and privacy security into its operations, continuously updating its practices to adhere to the latest changes in ISO/IEC 27001, BS 10012, and GDPR regulations. Dr. Fu emphasizes the firm’s strict adherence to these standards, stating, “BGI Genomics strictly follows the standards to set up and maintain information security and privacy management systems. The certification organizations review BGI Genomics’s management systems on-site annually to ensure they work and continue to meet the standards and criteria.”

The impact of these certifications extends beyond meeting legal obligations; they foster enhanced trust with clients and partners. BGI Genomics updated its privacy policy and cookie policy earlier in the year. Its 2024 work plan includes significant updates to its information security management system. backup protocols for electronic records, and permission management for shared disks.

About Dr. Fu Wei

Dr. Fu Wei is the Director of the Quality Management Department at BGI Genomics. In 2018, the Shenzhen Association for Quality recognized him as a person of outstanding quality. He helped the BGI Europe laboratory in Denmark achieve ISO 15189 and ISO/IEC 27001 certifications.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 3,000 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.